<DOC>
	<DOCNO>NCT00136565</DOCNO>
	<brief_summary>The purpose study determine efficacy safety profile toxicity combination Velcade™ ( bortezomib ) standard chemotherapy regimen ( ACVBP [ doxorubicin , cyclophosphamide , vindesine , bleomycin , prednisone ] ) treatment previously untreated patient peripheral T-cell lymphoma ( PTCL ) .</brief_summary>
	<brief_title>Study Bortezomib Combined With ACVBP Peripheral T-Cell Lymphoma</brief_title>
	<detailed_description>This multicentric , open-label , non-randomized , non-competitive clinical study , evaluate efficacy safety V-ACVBP chemotherapy previously untreated patient age 18 65 year peripheral T-lymphoma . It anticipate 60 subject enrol two year ( June 2005 May 2007 ) . The duration treatment period approximately 28 week patient follow death . The total duration study expect 5 year ( June 2005 May 2010 ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<criteria>Previously untreated noncutaneous peripheral Tcell lymphoma , include human Tcell lymphotropic virus type 1 ( HTLV1 ) relate Tcell lymphoma , natural killer ( NK ) cell lymphoma . Ages 18 65 year . Life expectancy &gt; 3 month . Written informed consent . Bcell lymphoma subtype Tcell lymphoma include anaplastic large cell lymphoma AKL ( + ) , lymphoblastic lymphoma primary cutaneous Tcell lymphoma . Any previous therapy lymphoma except shortterm corticosteroid inclusion . Inability tolerate ACVBP regimen accord investigator 's judgement . Positive serology HIV . Poor renal function ( creatinin &gt; 150 µmol/l within 14 day enrollment ) , poor liver function ( total bilirubin &gt; 30 µmol/l , transaminases &gt; 2.5 upper normal limit [ UNL ] within 14 day enrollment ) , unless abnormality relate lymphoma . Poor bone marrow reserve define neutrophil &lt; 1.5 G/l platelet &lt; 100 G/l within 14 day enrollment , unless abnormality relate lymphoma . Patient &gt; = grade 2 peripheral neuropathy nonrelated lymphoma . Any central nervous system ( CNS ) disease . CNS meningeal involvement lymphoma . Any serious active disease comorbidity accord investigator 's decision . Any history cancer last 5 year exception nonmelanoma skin tumour stage 0 ( situ ) cervical carcinoma . Known hypersensitivity bortezomib , boron mannitol . Contraindication cytotoxic drug contain chemotherapy regimen . Pregnant lactate woman woman childbearing potential willing use adequate method birth control ( i.e . hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Men agree take adequate contraceptive precaution study . Treatment investigational drug within 30 day plan first cycle chemotherapy study . Adult patient tutelage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>peripheral T-cell lymphoma</keyword>
	<keyword>bortezomib</keyword>
	<keyword>ACVBP regimen</keyword>
</DOC>